Multiple Myeloma in China
Overview
Multiple myeloma is a cancer of plasma cells in the marrow that produces abnormal proteins damaging bones, kidneys and blood counts. Once uniformly fatal, it is now a chronic disease for most patients through novel-agent induction, transplant and maintenance.
Chinese hematology centers treat very large myeloma populations, with full access to proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and CAR-T for relapsed disease.
Symptoms & Signs
Persistent bone pain, especially spine, ribs or hips, sometimes with fractures
Fatigue and weakness from anemia
Frequent infections from impaired antibody production
Excessive thirst and confusion from high calcium
Kidney impairment discovered on routine tests
Numbness or weakness from spinal cord compression by plasmacytoma — an emergency
Diagnosis
Serum and urine protein electrophoresis with immunofixation detecting monoclonal protein
Serum free light chain assay quantifying disease burden
Bone marrow biopsy with plasma cell percentage and cytogenetics
Whole-body low-dose CT or MRI skeletal survey mapping bone lesions
Kidney function and calcium assessment
FISH and NGS identifying risk-defining abnormalities such as del17p
Treatment Options
Induction therapy with triplet or quadruplet novel-agent combinations
Autologous stem cell transplantation consolidating first remission in fit patients
Maintenance therapy prolonging remission after transplant
Bisphosphonate-class or anti-RANKL therapy protecting bone
CAR-T cell therapy for multiply relapsed disease
Supportive care: hydration, infection prevention and renal management
Advanced Technologies & Novel Drug
Novel proteasome inhibitors and immunomodulatory agents as therapy backbones
BCMA-directed CAR-T approved for relapsed refractory myeloma
Minimal-residual-disease testing guiding treatment intensity
Anti-CD38 monoclonal antibodies in induction and relapse settings
Domestically developed novel agents available at Chinese hematology centers
Hospital & Specialist
- Peking University People's Hospital — Beijing
- Hospital of Hematology, Chinese Academy of Medical Sciences — Tianjin
- Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine — Shanghai
- Peking University First Hospital (PKUHSC) — Beijing
- Shen Zhi Xiang — Hematology
- Xu Ying — Hematology
- Liu Xiao Li — Hematology
- Li Jun Ling — Medical Oncology